Baidu
map

指南&解读指南

订阅

MedSci主页 / 所有栏目 / 指南&解读指南

风险最小化执行方案的制定和完善的技术指导原则

2008-05-08 国家药品监督管理局药品审评中心（CDE） CDE

临床试验

风险最小化执行方案的制定和完善的技术指导原则

中文标题：

风险最小化执行方案的制定和完善的技术指导原则

发布机构：

国家药品监督管理局药品审评中心（CDE）

发布日期：

2008-05-08

简要介绍：

风险最小化执行方案的制定和完善的技术指导原则

相关资料下载：
[AttachmentFileName(sort=1, fileName=风险最小化执行方案的制定和完善的技术指导原则.pdf)] GetToolGuiderByIdResponse(projectId=1, id=6cc111c002105a29, title=风险最小化执行方案的制定和完善的技术指导原则, enTitle=, guiderFrom=CDE, authorId=0, author=, summary=风险最小化执行方案的制定和完善的技术指导原则, cover=, journalId=0, articlesId=null, associationId=1936, associationName=国家药品监督管理局药品审评中心（CDE）, associationIntro=国家药品监督管理局药品审评中心（CDE）, copyright=0, guiderPublishedTime=Thu May 08 00:00:00 CST 2008, originalUrl=, linkOutUrl=, content=<p>风险最小化执行方案的制定和完善的技术指导原则</p>, tagList=[TagDto(tagId=109, tagName=临床试验)], categoryList=[CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=248, categoryName=真实世界研究, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指导原则, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=40, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3724, appHits=38, showAppHits=0, pcHits=239, showPcHits=3686, likes=0, shares=14, comments=7, approvalStatus=1, publishedTime=Thu Jul 01 14:56:58 CST 2021, publishedTimeString=2008-05-08, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=fbzhang, createdTime=Mon May 24 15:28:51 CST 2021, updatedBy=4754896, updatedName=fbzhang, updatedTime=Mon Jan 01 07:15:43 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=风险最小化执行方案的制定和完善的技术指导原则.pdf)])
风险最小化执行方案的制定和完善的技术指导原则.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=996462, encodeId=c15c99646264, content=hhhh, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dad5539561, createdName=ms2000001898877799, createdTime=Mon Jul 05 16:36:46 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995996, encodeId=b896995996b5, content=为了更好地学习和推广，建议少扣或不扣积分，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Jul 04 08:52:54 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995571, encodeId=145b9955e193, content=很好 很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c175540100, createdName=ms4000001832228962, createdTime=Sat Jul 03 01:07:15 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978634, encodeId=0e969e86343e, content=真好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3705526517, createdName=ACU97, createdTime=Thu Jul 01 15:38:38 CST 2021, time=2021-07-01, status=1, ipAttribution=)]
    2021-07-05 ms2000001898877799

    hhhh

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=996462, encodeId=c15c99646264, content=hhhh, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dad5539561, createdName=ms2000001898877799, createdTime=Mon Jul 05 16:36:46 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995996, encodeId=b896995996b5, content=为了更好地学习和推广，建议少扣或不扣积分，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Jul 04 08:52:54 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995571, encodeId=145b9955e193, content=很好 很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c175540100, createdName=ms4000001832228962, createdTime=Sat Jul 03 01:07:15 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978634, encodeId=0e969e86343e, content=真好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3705526517, createdName=ACU97, createdTime=Thu Jul 01 15:38:38 CST 2021, time=2021-07-01, status=1, ipAttribution=)]
    2021-07-04 微探

    为了更好地学习和推广，建议少扣或不扣积分，谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=996462, encodeId=c15c99646264, content=hhhh, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dad5539561, createdName=ms2000001898877799, createdTime=Mon Jul 05 16:36:46 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995996, encodeId=b896995996b5, content=为了更好地学习和推广，建议少扣或不扣积分，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Jul 04 08:52:54 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995571, encodeId=145b9955e193, content=很好 很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c175540100, createdName=ms4000001832228962, createdTime=Sat Jul 03 01:07:15 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978634, encodeId=0e969e86343e, content=真好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3705526517, createdName=ACU97, createdTime=Thu Jul 01 15:38:38 CST 2021, time=2021-07-01, status=1, ipAttribution=)]
    2021-07-03 ms4000001832228962

    很好 很实用

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=996462, encodeId=c15c99646264, content=hhhh, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dad5539561, createdName=ms2000001898877799, createdTime=Mon Jul 05 16:36:46 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995996, encodeId=b896995996b5, content=为了更好地学习和推广，建议少扣或不扣积分，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Jul 04 08:52:54 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995571, encodeId=145b9955e193, content=很好 很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c175540100, createdName=ms4000001832228962, createdTime=Sat Jul 03 01:07:15 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978634, encodeId=0e969e86343e, content=真好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3705526517, createdName=ACU97, createdTime=Thu Jul 01 15:38:38 CST 2021, time=2021-07-01, status=1, ipAttribution=)]
    2021-07-01 ACU97

    真好

    0

相关指南

NIH-FDA的2，3期临床试验方案模板

美国食品和药品监督管理局(FDA,Food and Drug Administration) · 2021-04-29

儿童用化学药品改良型新药临床试验技术指导原则（征求意见稿）

国家药品监督管理局药品审评中心（CDE） · 2021-04-13

药物临床试验适应性设计指导原则（试行）

国家药品监督管理局药品审评中心（CDE） · 2021-01-29

治疗脂代谢紊乱药物临床试验技术指导原则

国家药品监督管理局药品审评中心（CDE） · 2020-12-31

药物临床试验多重性问题指导原则（试行）（2020年）

国家药品监督管理局药品审评中心（CDE） · 2020-12-31

药物临床试验协变量校正指导原则（2020年）

国家药品监督管理局药品审评中心（CDE） · 2020-12-31

Baidu
map
Baidu
map
Baidu
map